Latest news with #Pharmacy
The Hindu
6 days ago
- General
- The Hindu
GITAM holds special graduation event for international students
GITAM Deemed to be University hosted its sixth special graduation ceremony on Wednesday for international students from Kenya, Rwanda, Bhutan, Nigeria, Nepal, Ethiopia, Uganda, and other nations. This year, 60 international students successfully completed programmes in disciplines of engineering, science, pharmacy, paramedical sciences, and management. Speaking at the event, Registrar Prof. D. Gunasekharan emphasised that India's educational landscape is rich in diversity, culture, and history, making it a preferred global destination for higher education. GITAM School of Pharmacy Principal Prof. Srinivas urged the graduates to apply their acquired knowledge towards building human capital in their home countries. He encouraged them to pursue research-driven careers to serve society. University Director (International Affairs) K.P.C. Kishan shared that over 400 students from 43 countries are currently enrolled at GITAM across various programs. He acknowledged the Central Government's `Study in India' initiative for promoting Indian higher education on the global stage. He invited graduates to join the Indian Alumni Association to stay connected and expand their professional networks globally.
National Post
27-05-2025
- Business
- National Post
US Food and Drug Administration (FDA) Grants Interchangeability Designation to Samsung Bioepis and Organon HADLIMA™ (adalimumab-bwwd) Injection
Article content HADLIMA™ (adalimumab-bwwd) injection, 40 mg/0.4 mL & 40 mg/0.8 mL is now interchangeable with all high- and low-concentration presentations (autoinjector, prefilled syringe, and single-dose vial) of Humira (adalimumab) 1,2 The interchangeability designation for HADLIMA is based on a Pharmacokinetics, Efficacy, Safety, and Immunogenicity study of SB5 versus Humira in patients with moderate to severe chronic plaque psoriasis 3 An interchangeable biosimilar product may be substituted for the reference product without consulting the prescriber, subject to state pharmacy laws 4 Article content Article content INCHEON, Korea & JERSEY CITY, N.J. — Samsung Bioepis Co., Ltd. and Organon & Co. (NYSE: OGN) today announced that the US Food and Drug Administration (FDA) has designated the HADLIMA™ (adalimumab-bwwd) high- and low-concentration (40 mg/0.4 mL, 40 mg/0.8 mL) autoinjectors and high-concentration prefilled syringe as interchangeable biosimilars to Humira ® (adalimumab). 2 These interchangeability designations follow the interchangeability designation received for the HADLIMA low-concentration (40 mg/0.8 mL) prefilled syringe and single-dose vial in June 2024. 1 With today's additional interchangeability designations, HADLIMA is now interchangeable with all presentations of the reference product. 1,2 An interchangeability designation enables a pharmacist to substitute the reference product with a biosimilar without the need to consult the prescriber, depending on state pharmacy laws. 4 Article content 'An increased uptake of biosimilars may lead to improved patient access to biologic therapies and potential savings for the US health care system. 5 As a company dedicated to making medicines more accessible, HADLIMA, now designated as fully interchangeable with the reference product, has a greater potential to bring savings for patients. 1,2,5 As our data shows, on average, patients paid more than four times as much out of pocket per month for Humira compared to HADLIMA,' *6 said Jon Martin, US Commercial Lead, Biosimilars and Established Brands at Organon. 'With this approval, pharmacies can substitute HADLIMA for the reference product Humira without consulting prescribers (subject to state law), which may facilitate increased access for patients to receive the medications they need.' 4,5 Article content 'This designation is meaningful as it signifies our continued commitment to making biosimilars more accessible. Both biosimilars and interchangeable biosimilars are highly similar and have no clinically meaningful differences in safety, purity, and potency compared to the reference product,' 7 said Byoung In Jung, Vice President and Regulatory Affairs Team Leader at Samsung Bioepis. 'With this designation, we continue to benefit patients, health care providers, and health care systems around the world.' Article content HADLIMA is a tumor necrosis factor (TNF) blocker indicated for appropriate patients with rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and uveitis. See full indications below. Patients treated with adalimumab products, including HADLIMA, are at increased risk for developing serious infections that may lead to hospitalization or death. Discontinue HADLIMA if a patient develops a serious infection or sepsis. Monitor patients closely for the development of signs and symptoms of infection during and after treatment with HADLIMA, including the possible development of tuberculosis (TB) in patients who tested negative for latent TB infection prior to initiating therapy. Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers including adalimumab products. See additional safety information below. Article content The interchangeability designation was based on clinical data from a randomized, double-blind, 1:1 ratio, parallel-group, multiple-dose clinical trial, which assessed pharmacokinetics (PK), efficacy, safety, and immunogenicity in two treatment groups: patients with moderate to severe plaque psoriasis who switched between formulations of EU-sourced Humira and high-concentration SB5 (adalimumab biosimilar) versus patients receiving Humira continuously. The study demonstrated comparability in terms of primary PK endpoints, as well as efficacy, safety, and immunogenicity profiles between the switching group and continuous Humira treatment group. 3 In addition, data from additional studies provide further evidence to support the interchangeability designation for HADLIMA low- and high-concentration autoinjectors. 8 Article content HADLIMA was first approved by the FDA in 2019 as a low-concentration (40 mg/0.8 mL) formulation of prefilled syringe and autoinjector. The high-concentration (40 mg/0.4 mL) formulation of prefilled syringe and autoinjector of HADLIMA was approved in 2022. 9 Both low- and high-concentration formulations of HADLIMA have been commercially available in the US market since 2023. 10 Article content Rheumatoid Arthritis: HADLIMA is indicated, alone or in combination with methotrexate or other non-biologic disease-modifying antirheumatic drugs (DMARDs), for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. Juvenile Idiopathic Arthritis: HADLIMA is indicated, alone or in combination with methotrexate, for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. Psoriatic Arthritis: HADLIMA is indicated, alone or in combination with non-biologic DMARDs, for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis. Ankylosing Spondylitis: HADLIMA is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis. Crohn's Disease: HADLIMA is indicated for the treatment of moderately to severely active Crohn's disease in adults and pediatric patients 6 years of age and older. Ulcerative Colitis: HADLIMA is indicated for the treatment of moderately to severely active ulcerative colitis in adult patients. Limitations of Use: The effectiveness of HADLIMA has not been established in patients who have lost response to or were intolerant to tumor necrosis factor (TNF) blockers. Plaque Psoriasis: HADLIMA is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. HADLIMA should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician. Hidradenitis Suppurativa: HADLIMA is indicated for the treatment of moderate to severe hidradenitis suppurativa in adult patients. Uveitis: HADLIMA is indicated for the treatment of non-infectious intermediate, posterior, and panuveitis in adult patients. Article content Active tuberculosis (TB), including reactivation of latent TB. Patients with TB have frequently presented with disseminated or extrapulmonary disease. Test patients for latent TB before HADLIMA use and during therapy. Initiate treatment for latent TB prior to HADLIMA use. Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Consider empiric anti-fungal therapy in patients at risk for invasive fungal infections who develop severe systemic illness. Bacterial, viral, and other infections due to opportunistic pathogens, including Legionella and Listeria. Article content Carefully consider the risks and benefits of treatment with HADLIMA prior to initiating therapy in patients: Article content Monitor patients closely for the development of signs and symptoms of infection during and after treatment with HADLIMA, including the possible development of TB in patients who tested negative for latent TB infection prior to initiating therapy. Article content Do not start HADLIMA during an active infection, including localized infections. Patients older than 65 years, patients with co-morbid conditions, and/or patients taking concomitant immunosuppressants may be at greater risk of infection. If an infection develops, monitor carefully and initiate appropriate therapy. Drug interactions with biologic products: A higher rate of serious infections has been observed in rheumatoid arthritis (RA) patients treated with rituximab who received subsequent treatment with a TNF blocker. An increased risk of serious infections has been seen with the combination of TNF blockers with anakinra or abatacept, with no demonstrated added benefit in patients with RA. Concomitant administration of HADLIMA with other biologic DMARDs (eg, anakinra or abatacept) or other TNF blockers is not recommended based on the possible increased risk for infections and other potential pharmacological interactions. Article content Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, including adalimumab products. Postmarketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type of T-cell lymphoma, have been reported in patients treated with TNF blockers, including adalimumab products. These cases have had a very aggressive disease course and have been fatal. The majority of reported TNF blocker cases have occurred in patients with Crohn's disease or ulcerative colitis and the majority were in adolescent and young adult males. Almost all of these patients had received treatment with azathioprine or 6-mercaptopurine concomitantly with a TNF blocker at or prior to diagnosis. It is uncertain whether the occurrence of HSTCL is related to use of a TNF blocker or a TNF blocker in combination with these other immunosuppressants. Article content Consider the risks and benefits of HADLIMA treatment prior to initiating or continuing therapy in a patient with known malignancy. In clinical trials, more cases of malignancies were observed among adalimumab-treated patients compared to control patients. Non-melanoma skin cancer (NMSC) was reported during clinical trials for adalimumab-treated patients. Examine all patients, particularly those with a history of prolonged immunosuppressant or psoralen and ultraviolet A (PUVA) therapy, for the presence of NMSC prior to and during treatment with HADLIMA. In adalimumab clinical trials, there was an approximate 3-fold higher rate of lymphoma than expected in the general U.S. population. Patients with chronic inflammatory diseases, particularly those with highly active disease and/or chronic exposure to immunosuppressant therapies, may be at higher risk of lymphoma than the general population, even in the absence of TNF blockers. Postmarketing cases of acute and chronic leukemia were reported with TNF blocker use. Approximately half of the postmarketing cases of malignancies in children, adolescents, and young adults receiving TNF blockers were lymphomas; other cases included rare malignancies associated with immunosuppression and malignancies not usually observed in children and adolescents. Article content Anaphylaxis and angioneurotic edema have been reported following adalimumab administration. If a serious allergic reaction occurs, stop HADLIMA and institute appropriate therapy. Article content Use of TNF blockers, including HADLIMA, may increase the risk of reactivation of hepatitis B virus (HBV) in patients who are chronic carriers. Some cases have been fatal. Article content Evaluate patients at risk for HBV infection for prior evidence of HBV infection before initiating TNF blocker therapy. Article content Exercise caution in patients who are carriers of HBV and monitor them during and after HADLIMA treatment. Article content Discontinue HADLIMA and begin antiviral therapy in patients who develop HBV reactivation. Exercise caution when resuming HADLIMA after HBV treatment. Article content TNF blockers, including adalimumab products, have been associated with rare cases of new onset or exacerbation of central nervous system and peripheral demyelinating diseases, including multiple sclerosis, optic neuritis, and Guillain-Barré syndrome. Article content Exercise caution when considering HADLIMA for patients with these disorders; discontinuation of HADLIMA should be considered if any of these disorders develop. Article content HEMATOLOGIC REACTIONS Article content Rare reports of pancytopenia, including aplastic anemia, have been reported with TNF blockers. Medically significant cytopenia has been infrequently reported with adalimumab products. Article content Consider stopping HADLIMA if significant hematologic abnormalities occur. Article content CONGESTIVE HEART FAILURE Article content Worsening and new onset congestive heart failure (CHF) has been reported with TNF blockers. Cases of worsening CHF have been observed with adalimumab products; exercise caution and monitor carefully. Article content Treatment with adalimumab products may result in the formation of autoantibodies and, rarely, in development of a lupus-like syndrome. Discontinue treatment if symptoms of a lupus-like syndrome develop. Article content IMMUNIZATIONS Article content Patients on HADLIMA should not receive live vaccines. Article content Pediatric patients, if possible, should be brought up to date with all immunizations before initiating HADLIMA therapy. Article content Adalimumab is actively transferred across the placenta during the third trimester of pregnancy and may affect immune response in the in utero -exposed infant. The safety of administering live or live-attenuated vaccines in infants exposed to adalimumab products in utero is unknown. Risks and benefits should be considered prior to vaccinating (live or live-attenuated) exposed infants. Article content ADVERSE REACTIONS Article content The most common adverse reactions in adalimumab clinical trials (>10%) were: infections (eg, upper respiratory, sinusitis), injection site reactions, headache, and rash. Article content Before prescribing HADLIMA, please read the Prescribing Information, including the Boxed Warning about serious infections and malignancies. The Medication Guide and Instructions for Use also are available. Article content Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing health care that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company. Samsung Bioepis continues to advance a broad pipeline of biosimilar candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology, hematology, nephrology, and endocrinology. For more information, please visit: and follow us on social media – X, LinkedIn. Article content Organon is an independent global healthcare company with a mission to help improve the health of women throughout their lives. Organon's diverse portfolio offers over 70 medicines and products in women's health, biosimilars, and a large franchise of established medicines across a range of therapeutic areas. In addition to Organon's current products, the company invests in innovative solutions and research to drive future growth opportunities in women's health and biosimilars. Organon is also pursuing opportunities to collaborate with biopharmaceutical partners and innovators who look to commercialize their products by leveraging Organon's scale and agile presence in fast growing international markets. Article content Organon has geographic scope with significant reach, world-class commercial capabilities, and approximately 10,000 employees with headquarters located in Jersey City, New Jersey. Article content HADLIMA is developed, manufactured and supplied by Samsung Bioepis, and commercialized by Organon. Samsung Bioepis and Organon have development and commercialization collaborations for two immunology products and one oncology product in the United States. Article content © 2025 Organon group of companies. All rights reserved. ORGANON and the ORGANON Logo are trademarks of the Organon group of companies. Article content HUMIRA is a trademark registered in the US by AbbVie Biotechnology Ltd.; Organon is not associated with this trademark owner. Article content Except for historical information, this press release includes 'forward-looking statements' within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including, but not limited to, statements about the potential benefits of biosimilars, as well as Organon's and Samsung's collaboration and the benefits thereof. Forward-looking statements may be identified by words such as 'may,' 'potential,' 'can,' 'should,' 'continue,' 'will,' 'expects,' 'future,' 'opportunity,' or words of similar meaning. These statements are based upon the current beliefs and expectations of Organon's management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate, or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Risks and uncertainties include, but are not limited to, expanded brand and class competition in the markets in which Organon operates; trade protection measures and import or export licensing requirements, including the direct and indirect impacts of tariffs (including any potential pharmaceutical sector tariffs), trade sanctions or similar restrictions by the United States or other governments; changes in U.S. and foreign federal, state and local governmental funding allocations including the timing and amounts allocated to Organon's customers and business partners; economic factors over which Organon has no control, including changes in inflation, interest rates, recessionary pressures, and foreign currency exchange rates; market volatility, downgrades to the U.S. government's sovereign credit rating or its perceived creditworthiness, changing political or geopolitical conditions, market contraction, boycotts, and sanctions, as well as Organon's ability to successfully manage uncertainties related to the foregoing; difficulties with performance of third parties Organon relies on for its business growth; the failure of any supplier to provide substances, materials, or services as agreed; the increased cost of supply, manufacturing, packaging, and operations; difficulties developing and sustaining relationships with commercial counterparties; restructurings or other disruptions at the FDA, the U.S. Securities and Exchange Commission ('SEC') and other U.S. and comparable government agencies; pricing pressures globally, including rules and practices of managed care groups, judicial decisions and governmental laws and regulations related to Medicare, Medicaid and health care reform, pharmaceutical reimbursement and pricing in general; the impact of higher selling and promotional costs; changes in government laws and regulations in the United States and other jurisdictions, including laws and regulations governing the research, development, approval, clearance, manufacturing, supply, distribution, and/or marketing of Organon's products and related intellectual property, environmental regulations, and the enforcement thereof affecting Organon's business; efficacy, safety or other quality concerns with respect to Organon's marketed products, whether or not scientifically justified, leading to product recalls, withdrawals or declining sales; future actions of third parties, including significant changes in customer relationships or changes in the behavior and spending patterns of purchasers of health care products and services, including delaying medical procedures, rationing prescription medications, reducing the frequency of physician visits and forgoing health care insurance coverage; legal factors that could preclude commercialization of products or negatively affect the profitability of existing products; the failure by Organon or its third party collaborators and/or their suppliers to fulfill our or their regulatory or quality obligations, which could lead to a delay in regulatory approval or commercial marketing of Organon's products; and volatility of commodity prices, fuel, shipping rates that impact the costs and/or ability to supply Organon's products. Organon undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in Organon's filings with the SEC, including Organon's most recent Annual Report on Form 10-K and subsequent SEC filings, available at the SEC's Internet site ( Article content *Based on an analysis of actual patient claims processed from July 2023 to August 2024, with the average out-of-pocket costs being $215 vs $48 for HUMIRA and HADLIMA, respectively. Article content 1 Approval letter for HADLIMA (adalimumab-bwwd) supplemental biologics license application 761059/S-018. U.S. Food and Drug Administration. June 2024. Article content 2 Approval letter for HADLIMA (adalimumab-bwwd) supplemental biologics license applications 761059/S-025 and 761059/S-026. U.S. Food and Drug Administration. May 2025. Article content 3 Feldman S, Valiukeviciene S, Pulka G, et al. Interchangeability of SB5 and adalimumab reference product in patients with moderate to severe chronic plaque psoriasis. Poster presented at: American Academy of Dermatology Annual Meeting; March 8-12, 2024; San Diego, CA. Accessed May 2025. Article content 4 US Food and Drug Administration. Biosimilar and interchangeable biologics; more treatment choices. Updated August 17, 2023. Accessed May 14, 2025. Article content 5 Aitken M, Kleinrock M, Pritchett J. Biosimilars in the United States 2023-2027: competition, savings, and sustainability. IQVIA Institute for Human Data Science. January 31, 2023. Accessed March 5, 2025. Article content 6 Data available on request from Organon Professional Services-DAP (Marketing Operations), 30 Hudson St., Jersey City, NJ 07302. Please specify information package REF-146241. Article content 7 Biosimilars: Review and approval. US Food and Drug Administration. December 13, 2022. Accessed May 16, 2025. Article content Article content Article content Article content Article content Contacts Article content Organon Media Contacts: Felicia Bisaro (646) 703-1807 Kate Vossen (732) 675-8448 Article content Investor Contacts: Jennifer Halchak (201) 275-2711 Renee McKnight (551) 204-6129 Article content Article content
Cision Canada
22-05-2025
- Business
- Cision Canada
GREY WOLF ANIMAL HEALTH REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS
TORONTO, May 22, 2025 /CNW/ - Grey Wolf Animal Health Corp. (TSXV: WOLF) ("Grey Wolf" or the "Company"), a Canadian diversified health company, today announced financial results for the three months ended March 31, 2025. Highlights Revenue for the quarter increased year over year by 31.0% to $7.9 million. Gross profit increased year over year by 34.0% to $4.2 million for the quarter. Adjusted EBITDA 1 increased year over year by 47.4% to $1.3 million for the quarter. Launched our first innovative small animal compounded product for the management of feline infectious peritonitis in cats. "We posted a solid first quarter for both revenue and Adjusted EBITDA," said Angela Cechetto, Chief Executive Officer. Ms. Cechetto went on to say, our growth was driven by an increase in our Pharmacy business by 66.1% to $5.2 million due to an increase in sales of compounded products and the full quarter impact of the acquisition of the Compounding Pharmacy of Manitoba (CPM). Excluding the impact of CPM, we experienced organic growth of 10.8% across our animal and human pharmacy businesses." Ms. Cechetto continued, "our Animal Health business unit saw a decline in revenue for the quarter of 6.5% to $2.7 million mainly due to a decline in sales of established products and offset by an increase in commissions and new products introduced during the prior year. We continued to experience softness in the veterinary channel carrying into the first quarter; however, we remain confident in the value of our product portfolio for animal health supported by the launch of new products at the end of 2024." Key Financial Data and Comparative Results Results of Operations for the First Quarter-ended March 31, 2025 Total revenue for the three-month period ended March 31, 2025 increased 31.0% to $7.9 million over the same period in 2024. Revenue in the Pharmacy business unit increased by 66.1% to $5.2 million from $3.1 million due to an increase in sales of compounded products and the impact of the acquisition of CPM. Revenue in the Animal Health business unit decreased by 6.5% to $2.7 million from $2.9 million mainly due to a decline in sales of established products and offset by an increase in commissions and new products introduced during the prior year. Gross profits for the three-month period ended March 31, 2025 were 52.6% compared to 51.5% for the same period in 2024. Gross profits were impacted by increased margins in the Pharmacy business unit as a result of decreased material and labour costs and the impact of the CPM acquisition, offset by reduced margins in the Animal Health business unit as a result of product mix. Total expenses for the three-month period ended March 31, 2025 increased 29.3% to $3.6 million over the same period in 2024. During the three-month period, there was an increase in salary, bonus, and benefits related to operational growth and the CPM Acquisition as compared to the same period in 2024, an increase in freight expenses related to the CPM Acquisition and one-time transaction costs related to the CPM Acquisition. Adjusted EBITDA 1 was $1.3 million in the first quarter 2025 compared to $0.9 million in the same period in 2024, mainly due to decreased net income for the period after adjusting the related impacts from the CPM Acquisition on interest and accretion expenses and depreciation and amortization cost, and transaction costs specific to the period ended March 31, 2025. Cash and cash equivalents were $6.8 million at March 31, 2025 compared to $6.4 million at December 31, 2024. The Company generated cash from operations of $1.1 million, which was primarily impacted by net income for the current period offset by changes in non-cash working capital items, most significantly changes in trade and other receivables, inventories, prepaid expenses, and accounts payable and accrued liabilities. As at March 31, 2025, the Company had outstanding borrowings of $26.4 million, of which $2.1 million are current and $24.3 million are non-current. The Company repaid borrowings of $0.5 million in the quarter. The Company's debt consists of three fixed rate term loans, including a mortgage of $4.4 million secured against the CPM land and building. The Company's net debt/Adjusted EBITDA 1 ratio is approximately 2.9x (2.3x excluding real estate) using 2024 proforma Adjusted EBITDA 1 of $6.7 million. Grey Wolf's financial statements and accompanying Management Discussion and Analysis for the three months ended March 31, 2025 are available under the Company's profile on 1 Non-IFRS Measures Management uses both IFRS and Non-IFRS Measures to assess the financial and operating performance of the Company's operations. These Non-IFRS Measures are not recognized measures under IFRS, do not have a standardized meaning under IFRS and are unlikely to be comparable to similar measures presented by other companies. The Non-IFRS Measures referenced in this press release includes Adjusted EBITDA. The Company defines Adjusted EBITDA as earnings before transaction costs (including, for greater certainty, transaction costs related to the CPM Acquisition), settlement costs, interest income, interest and accretion expense, income taxes, depreciation of property and equipment, depreciation of right of use assets, amortization of intangible assets, share-based compensation, foreign exchange gains or losses and other income The Company considers Adjusted EBITDA as an additional metric in assessing business performance and an important measure of operating performance and cash flow, providing useful information to help analyze and compare profitability between companies for investors and analysts. The following table provides a summary of the differences between Grey Wolf's consolidated IFRS and Non-IFRS financial measures, which are reconciled below: EBITDA and Adjusted EBITDA About Grey Wolf Animal Health Corp. Grey Wolf Animal Health Corp., headquartered in Toronto, Canada, is a diversified health company founded by a veterinarian to bring to market a broad portfolio of products that meets the unmet needs of veterinarians, physicians and patients. The Company's strategy is to in-license, acquire or compound prescription and non-prescription products for commercialization in the animal and human health market in Canada. For additional information, please visit: Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release. Forward Looking Statements Certain information included in this press release contains forward-looking information with the meaning of applicable Canadian securities laws. This information includes statements concerning the Company's objectives, its strategies to achieve those objectives, as well as statements with respect to management's beliefs, plans, estimates, and intentions, and similar statements concerning anticipated future events, results, circumstances, performance or expectations that are not historical facts. Forward-looking information generally can be identified by the use of forward-looking terminology such as "outlook", "objective", "may", "will", "would", "expect", "intend", "estimate", "anticipate", "believe", "should", "plan", "continue", or similar expressions suggesting future outcomes or events or the negative thereof. Such forward-looking information reflects management's beliefs and is based on information currently available. All forward-looking information in this press release is qualified by the following cautionary statements. Forward-looking information necessarily involve known and unknown risks and uncertainties, which may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, assumptions may not be correct and objectives, strategic goals and priorities may not be achieved. A variety of factors, many of which are beyond the Company's control, affect the operations, performance and results of the Company and its subsidiaries, and cause actual results to differ materially from current expectations of estimated or anticipated events or results. A more detailed assessment of the risks that could cause actual results to materially differ than current expectations is contained in the Risk Factors section of Grey Wolf's Management Discussion and Analysis for the three months ended March 31, 2025. The forward-looking information included in this press release is made as of the date hereof and should not be relied upon as representing the Company's views as of any date subsequent to the date hereof. Management undertakes no obligation, except as required by applicable law, to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise. SOURCE Grey Wolf Animal Health Corp.
Associated Press
31-03-2025
- Health
- Associated Press
Rite Aid Shares ‘ABCs' of Allergy Season to Help Nip Symptoms in the Bud
Millions of Americans greet spring's arrival with itchy eyes, runny noses and sneezing fits. Rite Aid is here to help customers manage those persistent allergy symptoms with simple solutions for the whole family before peak season arrives. 'At Rite Aid, we understand how spring allergies can disrupt daily life and dampen outdoor plans. Our knowledgeable pharmacists are available to help customers find the best solutions to help manage their allergy symptoms,' said Summer Kerley, Group Vice President, Pharmacy Growth and Clinical Programs. 'By sharing a few simple tips – such as keeping windows closed, choosing the right medication, or limiting time outdoors – Rite Aid is reinforcing our commitment to supporting communities with products and guidance they need to enjoy the season fully.' A – Antihistamines (And Other Allergy Relief Medicines). Choosing the right allergy medication can feel daunting with the number of options available. While antihistamines are the most common allergy relief medicine – blocking the chemical that triggers allergic symptoms like runny nose, sneezing, itchy or watery eyes – there are other options to help target additional allergy-related symptoms. Corticosteroids and decongestants aim to alleviate allergy symptoms by mitigating congestion and the body's natural inflammation response to hay fever, pollen, dust and other common allergens. For optimal results, it's recommended to take allergy medications 2 to 4 weeks in advance of peak allergy season to help mitigate symptoms effectively. Speak with your Rite Aid pharmacist about options to best address your symptoms. B – Be Mindful of Pollen Counts. Higher pollen counts are typically linked to a greater risk of allergic reactions. When pollen counts are high, minimize exposure by keeping windows closed and limiting outdoor activities. If you have been outside, change clothing and shower promptly to avoid bringing pollen indoors. C – Check the Label. It's important to take any medication as instructed on the label, especially allergy medicine, as some may cause drowsiness. Choose an age-appropriate formulation and follow the recommended dosage guidelines – use the correct amount, at the right time of day, for the recommended length of time. Most allergy medicines come in formulations for both children and adults. Customers can access additional allergy resources and find a range of over-the-counter remedies in-store or online at Rite Aid pharmacists can also help differentiate between a common cold and allergies and can create personalized treatment plans to meet the health and wellness needs of customers during allergy season and beyond. Rite Aid is a full-service pharmacy committed to improving health outcomes. Rite Aid is defining the modern pharmacy by meeting customer needs with a wide range of solutions that offer convenience, including retail and delivery pharmacy, as well as services offered through the Company's wholly-owned subsidiary Bartell Drugs. For more information, please visit Michelle McEnroe 717-975-5718 SOURCE: Rite Aid Corporation Copyright Business Wire 2025. PUB: 03/31/2025 09:30 AM/DISC: 03/31/2025 09:29 AM
Yahoo
03-03-2025
- Business
- Yahoo
SelectQuote Closes $350 Million Strategic Investment from Bain Capital, Morgan Stanley Private Credit and Newlight Partners
OVERLAND PARK, Kan., March 03, 2025--(BUSINESS WIRE)--SelectQuote, Inc. (NYSE: SLQT) (the "Company"), a leading distributor of Medicare insurance policies and owner of a rapidly-growing healthcare services platform, today announced that the Company closed and received the proceeds from the $350 million strategic investment on February 28, 2025. The Company originally announced a binding agreement on the transaction with funds managed by Bain Capital, Morgan Stanley Private Credit, and Newlight Partners on February 10th. The Company used $260 million of proceeds to pay down its outstanding term loan. The Company now has more than $100 million of available liquidity as it continues to focus on its industry-leading insurance distribution businesses and rapidly expanding healthcare services business. With the completion of this transaction, SelectQuote also appointed Chris Wolfe of Bain Capital Insurance and Srdjan Vukovic of Newlight Partners to the Board of Directors, each bringing over 20 years of investing and healthcare sector experience to the Company. For more information on this transaction, please reference the Company's 8-K filed with the Securities and Exchange Commission ("SEC") on February 10, 2025, which can be found on the SEC filings page of our website ( as well as Company's press release announcing the binding agreement ( About SelectQuote: Founded in 1985, SelectQuote (NYSE: SLQT) pioneered the model of providing unbiased comparisons from multiple, highly-rated insurance companies, allowing consumers to choose the policy and terms that best meet their unique needs. Two foundational pillars underpin SelectQuote's success: a strong force of highly-trained and skilled agents who provide a consultative needs analysis for every consumer, and proprietary technology that sources and routes high-quality leads. Today, the Company operates an ecosystem offering high touchpoints for consumers across insurance, pharmacy, and virtual care. With an ecosystem offering engagement points for consumers across insurance, Medicare, pharmacy, and value-based care, the company now has three core business lines: SelectQuote Senior, SelectQuote Healthcare Services, and SelectQuote Life. SelectQuote Senior serves the needs of a demographic that sees around 10,000 people turn 65 each day with a range of Medicare Advantage and Medicare Supplement plans. SelectQuote Healthcare Services is comprised of the SelectRx Pharmacy, a Patient-Centered Pharmacy Home™ (PCPH) accredited pharmacy, SelectPatient Management, a provider of chronic care management services, and Healthcare Select which proactively connects consumers with a wide breadth of healthcare services supporting their needs. View source version on Contacts Investor Relations:Sloan Bohlen877-678-4083investorrelations@ Media:Matt Sign in to access your portfolio
